{"id":"https://openalex.org/W4200112450","doi":"https://doi.org/10.3389/fimmu.2021.788499","title":"Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis","display_name":"Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis","alternate_titles":[],"publication_year":2021,"publication_date":"2021-12-08","ids":{"openalex":"https://openalex.org/W4200112450","doi":"https://doi.org/10.3389/fimmu.2021.788499","pmid":"https://pubmed.ncbi.nlm.nih.gov/34956219","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8692289"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2021.788499","doi":"https://doi.org/10.3389/fimmu.2021.788499","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2021.788499","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2021.788499/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4200112450"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2021.788499/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103112032","display_name":"Luke A. Moradi","orcid":"https://orcid.org/0000-0002-8055-6388","observed_orcids":["https://orcid.org/0000-0002-8055-6388"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luke A. Moradi","raw_affiliation_strings":["Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102501053","display_name":"Curtis A. Clark","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Curtis A. Clark","raw_affiliation_strings":["Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009585888","display_name":"Craig S. Schneider","orcid":"https://orcid.org/0000-0001-8133-1220","observed_orcids":["https://orcid.org/0000-0001-8133-1220"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Craig S. Schneider","raw_affiliation_strings":["Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001631400","display_name":"Alok S. Deshane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I58956616","display_name":"Case Western Reserve University","ror":"https://ror.org/051fd9666","country_code":"US","type":"education","lineage":["https://openalex.org/I58956616"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alok S. Deshane","raw_affiliation_strings":["Case Western Reserve University School of Medicine, Cleveland, OH, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Case Western Reserve University School of Medicine, Cleveland, OH, United States","institution_ids":["https://openalex.org/I58956616"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027367704","display_name":"Michael Christian Dobelbower","orcid":"https://orcid.org/0000-0003-0847-3016","observed_orcids":["https://orcid.org/0000-0003-0847-3016"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael C. Dobelbower","raw_affiliation_strings":["Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States","institution_ids":["https://openalex.org/I32389192"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5027367704"],"corresponding_institution_ids":["https://openalex.org/I32389192"],"apc_list":{"value":2950,"currency":"USD","value_usd":2950},"apc_paid":{"value":2950,"currency":"USD","value_usd":2950},"fwci":0.4776,"has_fulltext":true,"cited_by_count":7,"citation_normalized_percentile":{"value":0.60755288,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"12","issue":null,"first_page":"788499","last_page":"788499"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9589999914169312},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/radiotherapy","display_name":"radiotherapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/myasthenia-gravis","display_name":"myasthenia gravis","score":0.9589999914169312},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.8859999775886536},{"id":"https://openalex.org/keywords/prednisone","display_name":"prednisone","score":0.6589999794960022},{"id":"https://openalex.org/keywords/vedolizumab","display_name":"vedolizumab","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7919999957084656},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9359999895095825},{"id":"https://openalex.org/keywords/immunosuppression","display_name":"immunosuppression","score":0.7889999747276306},{"id":"https://openalex.org/keywords/tumor-regression","display_name":"tumor regression","score":0.5429999828338623},{"id":"https://openalex.org/keywords/autoimmune-disease","display_name":"autoimmune disease","score":0.5789999961853027}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8820766806602478},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8380954265594482},{"id":"https://openalex.org/C2778105408","wikidata":"https://www.wikidata.org/wiki/Q8285","display_name":"Myasthenia gravis","level":2,"score":0.8141705989837646},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.6703693270683289},{"id":"https://openalex.org/C2780194698","wikidata":"https://www.wikidata.org/wiki/Q6005429","display_name":"Immune dysregulation","level":3,"score":0.529649019241333},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.5093842148780823},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5049427151679993},{"id":"https://openalex.org/C2780252810","wikidata":"https://www.wikidata.org/wiki/Q1455316","display_name":"Immunosuppression","level":2,"score":0.46992194652557373},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4689925014972687},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.45486918091773987},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.45000553131103516},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.430766224861145},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4113154411315918},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3943178057670593},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39184290170669556},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3292366862297058},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.11482128500938416}],"mesh":[{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003092","descriptor_name":"Colitis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D003092","descriptor_name":"Colitis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D003092","descriptor_name":"Colitis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003092","descriptor_name":"Colitis","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D009157","descriptor_name":"Myasthenia Gravis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D009157","descriptor_name":"Myasthenia Gravis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009157","descriptor_name":"Myasthenia Gravis","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D011241","descriptor_name":"Prednisone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D016867","descriptor_name":"Immunocompromised Host","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059248","descriptor_name":"Chemoradiotherapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.3389/fimmu.2021.788499","doi":"https://doi.org/10.3389/fimmu.2021.788499","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2021.788499","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2021.788499/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmid:34956219","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34956219","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Case Reports"},{"id":"pmh:oai:pubmedcentral.nih.gov:8692289","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8692289/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:cf2387b9d6ca43e3930e437949233edb","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/cf2387b9d6ca43e3930e437949233edb","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 12 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2021.788499","doi":"https://doi.org/10.3389/fimmu.2021.788499","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2021.788499","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2021.788499/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4200112450.pdf","grobid_xml":"https://content.openalex.org/works/W4200112450.grobid-xml"},"referenced_works_count":10,"referenced_works":["https://openalex.org/W2108789863","https://openalex.org/W2140231263","https://openalex.org/W2592187743","https://openalex.org/W2788208686","https://openalex.org/W2913383852","https://openalex.org/W2917853396","https://openalex.org/W2965794029","https://openalex.org/W3018562618","https://openalex.org/W3049175319","https://openalex.org/W3092186599"],"related_works":["https://openalex.org/W2342106031","https://openalex.org/W2337577452","https://openalex.org/W2991269534","https://openalex.org/W7160992575","https://openalex.org/W2937704739","https://openalex.org/W2913723273","https://openalex.org/W2537763371","https://openalex.org/W4389289255","https://openalex.org/W2917853396","https://openalex.org/W3008977870"],"abstract_inverted_index":{"Immune":[0],"checkpoint":[1],"inhibitors":[2],"(ICIs)":[3],"and":[4,32,99,105,112,122,141],"radiotherapy":[5],"(RT)":[6],"combinations":[7],"for":[8,77,118,124],"various":[9],"metastatic":[10,100],"cancers":[11],"are":[12],"increasingly":[13],"utilized,":[14],"yet":[15,84],"the":[16,67,137],"augmentation":[17],"of":[18,64,69,92,144],"anti-cancer":[19],"immunity":[20],"including":[21,37],"distant":[22],"tumor":[23,30,57],"responses":[24],"by":[25],"RT":[26,114],"remains":[27,49],"ill-characterized.":[28],"Immunosuppressive":[29],"microenvironments":[31],"defective":[33],"anti-tumor":[34],"immune":[35,52,155],"activation":[36],"immune-related":[38],"adverse":[39,154],"events":[40],"(irAEs)":[41],"likely":[42],"limit":[43],"dramatic":[44,55],"immuno-radiotherapy":[45,159],"combinations,":[46],"though":[47],"it":[48],"unclear":[50],"which":[51],"characteristics":[53],"mediate":[54],"systemic":[56,107],"regression":[58,108],"in":[59,72,147],"only":[60],"a":[61,90,93],"small":[62],"subset":[63],"patients.":[65],"Moreover,":[66],"efficacy":[68],"ICI":[70],"treatment":[71],"patients":[73,148],"receiving":[74,110,158],"immunosuppressive":[75,145],"therapies":[76],"autoimmune":[78,151],"conditions":[79],"or":[80,153],"irAEs":[81],"is":[82],"convoluted,":[83],"clinically":[85],"valuable.":[86],"Here,":[87],"we":[88],"report":[89],"case":[91],"75-year-old":[94],"man":[95],"with":[96,149],"myasthenia":[97,119],"gravis":[98,120],"melanoma":[101],"who":[102],"experienced":[103],"complete":[104],"durable":[106],"after":[109,127],"pembrolizumab":[111,133],"single-lesion":[113],"while":[115,157],"on":[116,132],"prednisone":[117],"prophylaxis":[121],"vedolizumab":[123],"immune-mediated":[125],"colitis":[126],"previously":[128],"experiencing":[129],"mixed":[130],"response":[131],"monotherapy.":[134],"We":[135],"discuss":[136],"potential":[138],"paradoxical":[139],"effects":[140],"clinical":[142],"considerations":[143],"regimens":[146],"underlying":[150],"disease":[152],"reactions":[156],"combinations.":[160]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4200112450","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2021-12-31T00:00:00"}
